Related Articles
Comparison of the effectiveness of erlotinib, gefitinib, and afatinib for treatment of non‑small cell lung cancer in patients with common and rare EGFR gene mutations
Predictive factors in patients with EGFR mutation‑negative non‑small cell lung cancer treated with erlotinib
Clinical significance of epidermal growth factor receptor mutations and insulin-like growth factor 1 and its binding protein 3 in advanced non-squamous non-small cell lung cancer
Gefitinib as first line therapy in Malaysian patients with EGFR mutation-positive non-small-cell lung cancer: A single-center retrospective study
Phase II study of erlotinib for previously treated patients with EGFR wild‑type non‑small‑cell lung cancer, following EGFR mutation status reevaluation with the Scorpion Amplified Refractory Mutation System